The shared genetic basis of attention deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs) was explored by investigating the association of candidate risk factors in neurotransmitter genes with both disorders. One hundred seven methadone maintenance treatment patients, 36 having an ADHD diagnosis, 176 adult patients with ADHD without SUDs, and 500 healthy controls were genotyped for variants in the DRD4 (exon 3 VNTR), DRD5 (upstream VNTR), HTR1B (rs6296), DBH (rs2519152), COMT (rs4680; Val158Met), and OPRM1 (rs1799971; 118A4G) genes. Association with disease was tested using logistic regression models. This pilot study was adequately powered to detect larger genetic effects (ORZ2) of risk alleles with a low frequency. Compared to controls, ADHD patients (with and without SUDs) showed significantly increased frequency of the DBH (rs2519152: OR 1.73; CI 1.15-2.59; P= 0.008) and the OPRM1 risk genotypes (rs1799971: OR 1.71; CI 1.17-2.50; P= 0.006). The DBH risk genotype was associated with ADHD diagnosis, with the association strongest in the pure ADHD group. The OPRM1 risk genotype increased the risk for the combined ADHD and SUD phenotype. The present study strengthens the evidence for a shared genetic basis for ADHD and addiction. The association of OPRM1 with the ADHD and SUD combination could help to explain the contradictory results of previous studies. The power limitations of the study restrict the significance of these findings: replication in larger samples is warranted.
Introduction
Both attention deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs) are quite prevalent, with estimated prevalences in the adult population of 3.4% and 9.2% respectively (Fayyad et al., 2007; Substance Abuse and Mental Health Services Administration, 2007) . These disorders are highly heritable and are accompanied by substantial rates of psychiatric comorbidity. Moreover, they frequently coexist (Wilens, 2007) . Although there are clear indications that the psychiatric symptoms and conduct disturbances associated with ADHD have a causative role in the development of problematic drug use and addiction (Elkins et al., 2007; Roy, 2008) , there are also indications of a genetic basis for the overlap (Groman et al., 2009; Wilens, 2004) . ADHD is more prevalent in families of probands with SUDs (Clark et al., 2004; Knopik et al., 2009; Marmorstein et al., 2009; Wilens et al., 2005) , and SUDs are more frequent among family members of ADHD patients (Biederman et al., 1992; Faraone et al., 2000; Milberger et al., 1998) . Indeed, a study assessing both ADHD and SUDs in families of ADHD probands revealed evidence for a shared familiality of ADHD and drug use disorders with variable expression .
The genetic risk factors common to ADHD and SUDs have not yet been identified, mostly because the etiologies of the two disorders are still largely unknown. The most attention has been focused on neurotransmitter systems involved in the pathophysiology of the two disorders, especially the dopaminergic system; dopamine is the primary neurotransmitter of the central motivation system, which plays a crucial role in addiction (Koob and Volkow, 2010; Volkow et al., 2009) . Dopamine is also implicated in ADHD, mainly due to the therapeutic effects of stimulant medication, which inhibits the reuptake of dopamine Tripp and Wickens, 2009 ). Serotonin dysregulation is also hypothesised to play a causal role in ADHD and addiction (Oades, 2008; Ribases et al., 2009; Ross and Peselow, 2009) . Genetic determinants of variability in these neurotransmitter systems have been studied in both disorders, with controversial results Kreek et al., 2005; Yuferov et al., 2010) . In cases where particular variants conveying an increased risk were described, the results have proven difficult to reproduce. This is because the impact of each variant is quite small, attesting to the polygenic nature of the two disorders (Faraone and Mick, 2010; Wong and Schumann, 2008) .
Direct comparison studies of risk genotypes in different patient populations are rather scarce. A recent assembly of both clinical and genetic data from different populations allowed us to explore the role of a limited number of genetic polymorphisms in the proposed shared predisposition to ADHD and SUDs. Due to the limited size of the project, a pragmatic choice was made to study six welldocumented polymorphisms of the genes DRD4, DRD5, HTR1B, DBH, COMT, and OPRM1, previously used in association studies of ADHD and/or SUDs. It is important to point out that most family studies on the genetics of ADHD (indeed, most of the studies mentioned below) were carried out in child and adolescent populations. However the available scientific information indicates that the heritability of clinically diagnosed childhood and adult ADHD is quite similar. Moreover results of candidate gene as well as genome-wide molecular genetic studies in adult ADHD samples implicate some of the same genes involved in ADHD in children, although in some cases different alleles and different genes may be responsible for adult versus childhood ADHD (Franke et al., 2011) .
The dopamine D4 and D5 receptors are well represented in the frontal-subcortical networks implicated in the pathophysiology of ADHD, as shown by neuroimaging and neuropsychological studies (Brennan and Arnsten, 2008; Curatolo et al., 2009) . Most molecular genetic studies of DRD4 in ADHD have focused on a variable number of tandem repeat polymorphisms (VNTRs), which consist of a 48 base-pair (bp) repeat unit that codes an amino-acid sequence located in the third cytoplasmic loop of the receptor. This sequence is thought to be involved in G-protein coupling (DiMaio et al., 2003) . The association of the 7-repeat allele with ADHD has been confirmed in three meta-analyses Gizer et al., 2009; Li et al., 2006) , and was used as the risk allele in this study. The DRD4 polymorphism has not been studied extensively in substance use disorders, except for a Hungarian study of addicted patients which failed to reveal a significant association with addiction (Szilagyi et al., 2005) . The most widely studied polymorphism, our choice for this study, of the dopamine D5 receptor (DRD5) is a dinucleotide repeat that maps approximately 18.5 kb upstream of the transcription start site (Hawi et al., 2003) . The common 148-bp repeat allele is clearly associated with ADHD (Gizer et al., 2009; Li et al., 2006; Lowe et al., 2004; Maher et al., 2002) . No significant association of this allele with SUDs has yet been identified (Le Foll et al., 2009) .
Serotonin dysregulation has been related to impulsive behaviour (Dalley et al., 2008) and thus hypothesised to play a causal role in ADHD. A modest but significant association between ADHD and a G4C transition at nucleotide position 861 (861G4C; rs6296) of the serotonin 1b receptor (HTR1B; 5-HT1B) gene has been confirmed in a recent meta-analysis (Gizer et al., 2009; Hawi et al., 2002) and was selected for the current study. Because the serotonin system is also involved in drug and alcohol dependence, the role of this same single nucleotide polymorphism (SNP) has been studied in addiction, and its association with a history of substance use disorder has been reported in three studies (Yuferov et al., 2010) . However, no association with the rs6296 SNP was found in a study of heroin addiction, although nominally significant associations of heroin dependence with other polymorphisms in the HTR1B genome were identified (Proudnikov et al., 2006) . Dopamine beta-hydroxylase (DBH) is the primary enzyme responsible for the conversion of dopamine to norepinephrine. A significant association of ADHD with a SNP in intron 5 of the DBH gene, which results in the creation of a TaqI restriction enzyme site sequence (rs2519152), was first reported by Daly et al. (1999) . A recent meta-analysis of attempted replications of this finding failed to reach statistical significance, indicating a trend towards an association of rs2519152 with ADHD (Gizer et al., 2009) ; we took this variant as our risk polymorphism. There have been few studies of SUD associations and these have yielded inconsistent results (Kreek et al., 2005) .
Catechol-O-methyl-transferase (COMT) is responsible for the degradation of the catecholamines dopamine and norepinephrine. This enzyme is very active in the frontal lobe, where it plays an important role in regulating synaptic dopamine levels. The most studied polymorphism of COMT is a functional SNP that generates a valine to methionine substitution (Val158Met), which results in decreased enzymatic activity and increased dopamine in the prefrontal cortex (Chen et al., 2004) . Studies of this variation in ADHD have yielded equivocal results, and a recent meta-analysis indicates no association of this polymorphism with the disorder (Gizer et al., 2009 ). However, the Val allele of the Val158Met polymorphism has been linked with aggressiveness and conduct disorder symptoms; this association with conduct disorder has been replicated in ADHD patients (Caspi et al., 2008; Deyoung et al., 2009; Langley et al., 2010) . Among all the childhood psychiatric disorders, conduct disorder carries the highest risk of later SUD development (Roy, 2008) . In the present study the Val allele was considered the risk allele.
The OPRM1 gene codes for the m-opioid receptor, which is the molecular target for endogenous opioid peptides as well as for morphine and other opioids. Due to this receptor's crucial role in opioid tolerance and dependence, variations in its genetic code receptor have been implicated not only in opioid dependence but also in other SUDs. As our risk variant we took one of the most studied variants of the receptor genome is the 118A4G (rs1799971) SNP, which alters the amino acid sequence of the receptor. Although some studies have found a significant association of this SNP with opioid dependence (Bart et al., 2004; Drakenberg et al., 2006; Kreek et al., 2005) and other SUDs (van der Zwaluw et al., 2007) , a recent meta-analysis found no significant evidence for either a dominant or additive effect of this polymorphism on the risk of opioid dependence (Glatt et al., 2007) . Although there have been no investigations of this variant in ADHD, recent research suggests a role for the opioid system in impulse control disorders (Olmstead et al., 2009 ).
Starting from the hypothesis of a shared genetic basis for ADHD and SUDs, we proposed that some risk genotypes are associated with one of them alone, whereas others are associated with their combination. We tested this hypothesis in an exploratory study using genetic material from three previous studies. However, not enlarging our study samples and using only available material restricted the possibility to sufficiently power the study for optimal significance.
Materials and methods

Study populations
In the present analysis genetic material from three different study samples was used: 1) Methadone maintenance patients (n=107, 81.3% men, mean age 41.2 years, age range 24-59). An extensive assessment was recently performed of the psychiatric comorbidity (including ADHD) of 197 opioid-dependent patients in long-term methadone maintenance treatment (Carpentier et al., 2012 (Carpentier et al., , 2009 (Carpentier et al., , 2011 . ADHD diagnoses were based on information obtained from semi-structured interviews. The interview protocol, which is based on the DSM-IV definition of ADHD, assesses both the childhood and current presence of three symptom classes (inattention, restlessness, and impulsivity) and the resulting dysfunction (Kooij, 2002; Kooij et al., 2008 Kooij et al., , 2004 . If possible, partners or relatives were contacted to confirm the information. During this study a majority of participants agreed to provide a blood or saliva sample for genetic analysis. Patients of non-Caucasian origin were excluded from the analyses reported here, as were patients with an insufficiently substantiated ADHD diagnosis. This left us with a final selection of 107 samples, from 36 patients diagnosed as having ADHD and 71 patients diagnosed as not having ADHD respectively.
2) Adult ADHD patients (n=176, 47.7% men, mean age 37.1 years, age range 18-65). Adult patients with persistent ADHD were recruited as part of the International Multicentre Persistent ADHD CollaboraTion (IMpACT) (Franke et al., 2010) from two treatment centres in The Netherlands. All patients were evaluated by experienced psychiatrists; the diagnosis of persistent ADHD was based on DSM-IV criteria (Franke et al., 2008) . All the patients were ethnic Caucasian. Screening for SUDs was part of the clinical evaluation.
3) Healthly control subjects (n=500, 49.4% men, mean age 59.4 years, age range 22-92). Controls of Caucasian origin were recruited as part of the Nijmegen Biomedical Study (Hoogendoorn et al., 2006 ), a population-based survey conducted by the Department of Epidemiology and Biostatistics and the Department of Clinical Chemistry of the Radboud University Nijmegen Medical Centre. A random sample of 21,756 residents of the municipality of Nijmegen, stratified by age and sex, received an invitation to fill out a postal questionnaire on lifestyle and medical history. Forty-three per cent of the sample (N=9350) returned valid questionnaires; 69% of participants (N=6468) also donated a blood sample. The subjects were asked to complete the adult ADHD DSM-IV-TR Rating Scale for current symptoms (Kooij et al., 2005) . All those reporting four or more positive symptoms on this screening list were excluded from the analyses. The control group was not specifically screened for SUDs.
For all three samples, the approval of the study design and proceduce by the appropriate ethics committee and the informed consent procedure are documented in the original study reports (Carpentier et al., 2011; Franke et al., 2010; Hoogendoorn et al., 2006) . Groups and subgroups based on ADHD and SUD status were formed from the two patient samples (Table 1) . The ADHD_all group included all patients with ADHD (both with and without SUDs). The ADHD_pure subgroup was restricted to patients with ADHD only. The ADHD&SUD_pure subgroup consisted of patients with both disorders. Patients with SUDs only formed the SUD_pure subgroup. Finally, the SUD_all group included all patients with SUDs.
Laboratory methods
Genotyping was performed on DNA isolated from blood or saliva using standard protocols. Generally, 5% blanks as well as duplicates in and between plates were included as quality controls during genotyping. All genetic analyses were performed at a CCKLcertified laboratory at the Department of Human Genetics in Nijmegen.
Genotyping of DRD4 (exon 3 VNTR) and DRD5 (upstream VNTR) was performed using Fragment Length Analysis. The PCR reaction of the DRD4 was assessed using 50 ng of genomic DNA, 1.25 mM of the fluorescent-labelled forward primer 5 0 -Vic-GCGACTACGTGGTC-TACTCG-3 0 , 1.25 mM of the reverse primer with PIG tail The PCR-products of DRD4 and DRD5 were combined by diluting the DRD4 product 100 times and the DRD5 product 10 times. One microliter of the result, combined with 9.7 ml of formamide and 0.3 ml of Genescan-600 LIZ Size Standard (Applied Biosystems), was analysed using a 3730 Genetic Analyzer (Applied Biosystems) according to the protocol of the manufacturer.
The HTR1B polymorphism rs6296 was genotyped using a Taqman analysis (assay ID: Taqman assay: C___2523534_20 Applied Biosystems). Genotyping was performed in a 10 ml solution containing 10 ng of genomic DNA, 5 ml of Taqman Mastermix (2 Â ; Applied Biosytems), 0.125 ml of the Taqman assay, and 3.875 ml of water, using a 7500 Fast Real-Time PCR System. The genotypes were scored using the algorithm and software supplied by the manufacturer (Applied Biosystems).
The DBH polymorphism rs2519152 was genotyped using a restriction-fragment length polymorphism (RFLP) analysis. PCR was performed on 50 ng of genomic DNA using 0.4 mM of the forward primer 5 0 -AGGCATTTTACTACCCAGAGG-3 0 , 0.4 mM of the reverse primer 5 0 -CTGTATTTGGAACTTGGCATC-3 0 , 0.25 mM of dNTPs, and 0.5 U of Taq DNA polymerase (Invitrogen, Breda, The Netherlands) in a PCR buffer containing 10 mM of Tris-HCl pH 8.0, 50 mM of KCl, 0.1% Triton X-100 (v/v), 0.015% gelatin (w/v), 5% DMSO (v/v), and 1.5 mM of MgCl 2 . The cycling conditions were 5 min at 92 1C, followed by 35 cycles of 1 min at 92 1C, 1 min at 61 1C, 1 min at 72 1C, and lastly 10 min at 72 1C. To purify the PCR-product, NucleoFast96 plates (Macherey-Nagel, Düren, Germany) were used. An enzyme restriction reaction was subsequently produced in a 15 ml solution consisting of 10 ml of purified PCR-product, 5 U of TaqI restriction enzyme, 1 Â NEBuffer 3, and 1 Â bovine serum albumin. Digestion was produced at 65 1C for 4 h, which resulted in two fragments of 297 bp and 167 bp for the homozygous T genotype; the homozygous C variant remained uncut (464 bp).
The COMT polymorphism (rs4680) was genotyped using Taqman analysis (assay ID: Taqman assay: C__25746809_50; reporter 1: VIC-A-allele, reverse assay; Applied Biosystems), in a 10 ml solution consisting of 10 ng of genomic DNA, 5 ml of Taqman Mastermix (2 Â ; Applied Biosytems), 0.125 ml of the Taqman assay, and 3.875 ml of water, on a 7500 Fast Real-Time PCR System. The genotypes were scored using the algorithm and software supplied by the manufacturer (Applied Biosystems).
The OPRM1 polymorphism (rs1799971) was genotyped again using Taqman analysis (assay ID: Taqman assay: C___8950074_1_; reporter 1: VIC-A-allele, forward assay; Applied Biosystems), in a 10 ml solution consisting of 10 ng of genomic DNA, 5 ml of Taqman Mastermix (2 Â ; Applied Biosytems), 0.25 ml of the Taqman assay, and 3.75 ml of water, and performed on a 7500 Fast Real-Time PCR System. The genotypes were scored using the algorithm and software supplied by the manufacturer (Applied Biosystems).
Statistical analysis
We determined allelic frequencies in all three samples. Starting from a dominant model of inheritance for each risk allele, we calculated the frequency of the risk allele carriers (both homozygous and heterozygous) in the different groups and subgroups. For each risk polymorphism we defined the risk group/genotype as comprising both the homozygous and heterozygous carriers of the minor allele (in case of HTR1B and OPRM1), the major allele for DBH, the Val-allele for COMT, the 7-repeat allele for DRD4 and the 148-bp repeat allele for DRD5.
Hardy-Weinberg equilibrium (HWE) was assessed for each genetic variant tested using standard methods and using a p-value cut-off of 0.05. To analyse the association between the selected genetic variants and the risk of ADHD, a logistic regression was performed comparing the ADHD_all group and the control group with gender as the covariate. To account for multiple analyses, the significance Table 1 Gender distribution in the study populations, and formation of comparison groups and subgroups based on ADHD and SUD status from two patient samples (MMT patients: N= 107; ADHD patients: N = 176). N N Male (%) n ADHD_all n ADHD_pure n ADHD&SUD _pure n SUD_pure n SUD_all MMT: methadone maintenance treatment.
level was adjusted using a Bonferroni correction (P/n: significance level divided by number of tests). If a risk genotype showed a significant increase in the odds ratio (OR), a post-hoc logistic regression was carried out for this genotype in each patient group and subgroup compared to the control group, again with gender as a covariate. As the subgroup analysis explored the basis of the associations found in the entire group, an additional Bonferroni adjustment was deemed to be an overcorrection, and the same corrected significance level was used. All statistical analyses were performed using Statistical Package for the Social Sciences 15.0.1, 2006 (SPSS Inc., Chicago, Ill., USA). Performing a power analysis using the 'Genetic Power Calculator' (http://pngu.mgh.harvard.edu/~purcell/gpc/) we found that at a power level of 0.80, assuming a dominant model of inheritance and perfect linkage desequilibrium between the causal variant and the markers used, the study is adequately powered to detect in the total group (ADHD patients: N=283) larger genetic effects (ORZ2) of risk alleles with a moderate (=0.25) to low (r0.10) frequency.
Results
The prevalence of the six risk allele carriers in the different groups and subgroups is listed in Table 2 . Table 3 shows the ORs for the risk allele carriers in the ADHD_all group compared to the control group. After the Bonferroni correction, a significant association with disease was found for the DBH (OR 1.73; CI 1.15-2.59; P= 0.008) and the OPRM1 (OR 1.71; CI 1.17-2.50; P=0.006) risk genotypes. The covariate Gender had no significant effect.
A more detailed analysis of these two risk allele carriers in the different patient groups revealed clearly divergent patterns (Table 4 ). The DBH risk genotype (comprising homozygous and heterozygous expressions of the DBHintron5-C4T allele) was specifically associated with ADHD diagnosis, with the highest OR in the ADHD_pure subgroup (ADHD but not SUD: OR 1.97; CI 1.25-3.10; P= 0.003). For the OPRM1 risk genotype (the homozygous and heterozygous OPRM1 118A4G genotypes), the largest OR was found in the ADHD&SUD_pure subgroup (combined ADHD and SUDs: OR 2.75; CI 1.35-5.72; P=0.007). The covariate Gender appeared to have an important effect in the SUD subgroups (Table 4) ; this was due to the important gender disparity in the SUD patient group.
Discussion
The results of this exploratory investigation confirm our hypothesis that specific genotypes increase the risk for ADHD only, whereas others convey an increased risk for the combination of ADHD and SUD. The findings for the DBH risk genotype are in accordance with the literature: up to now, only the association of this genotype with ADHD, but not with SUD, has been replicated (Gizer et al., 2009; Kreek et al., 2005) . The present findings suggest that the inconsistent results in SUD patients could result from the significant prevalence of (undiagnosed) ADHD in these patient populations (Levin et al., 1998; Schubiner et al., 2000; Wilens, 2004) . The OPRM1 findings are interesting, as the association of OPRM1 118A4G with the ADHD and SUD combination has not been previously documented. In this study the increased prevalence of the risk genotype in SUD groups was primarily due to a concentration of the risk genotype in patients with both SUD and ADHD, while the prevalence in patients with only SUD was strikingly low (Table 2) . Interestingly, this specific association can help explain the contradictory findings for this gene in previous studies of patients with SUD (Glatt et al., 2007; van der Zwaluw et al., 2007) ; in these studies, the influence of comorbid ADHD was not taken into account. As the endogenous opioid system has not yet been implicated in the neurobiology of ADHD, the connection between ADHD and the risk genotype addressed in the present study remains unclear, as it has not been examined in previous studies. However, it is relevant to note that the opioid system could be involved in the disturbances of reward and reinforcement regulation, observed in ADHD, particularly the impaired signalling of delayed rewards arising from disturbances in motivational processes (Sonuga-Barke, 2003) . The same polymorphism of the m-opioid receptor gene (OPRM1) has been associated with dispositional and neural sensitivity to social rejection (Way et al., 2009 ) and parent-child relations (Copeland et al., 2011) , implicating the opioid (reward) system in the regulation of social relations and behaviour. The present findings suggest a specific pathophysiological role for the opioid system in the increased vulnerability to both behaviour disturbance (ADHD) and problematic substance use.
Despite its small size, the present study confirms the value of recognising the shared heritability of ADHD and addiction, and it demonstrates that taking comorbidity into account can help us understand the association of psychiatric disorders with specific genes. Further study of the genetic basis of addiction in ADHD patients could allow us to determine whether these genes exert their influence primarily at the neurobiological, behavioural, or social/emotional level, thereby helping us elucidate the pathophysiology and the link between the two disorders.
As the genetics of ADHD remain largely undetermined, assessing comorbidity in ADHD patients could be a productive way to identify reliable subtypes of ADHD and create more homogeneous study samples, thereby enabling a more specific association of ADHD with genetic risk factors (Buitelaar, 2005; Levy and Ebstein, 2009 ). The present findings also have implications for patient care. Their replication could lead to the identification of the ADHD and SUD combination as a specific genetic subtype of ADHD. Such identification would be in accordance with the observation that the risk for problematic substance use is not evenly distributed among ADHD patients. Indeed, the majority of ADHD patients do not show problematic substance use. From both the therapeutic and preventive perspectives, it is important to know in what respects ADHD patients with increased SUD risk differ from ADHD patients with no addiction and how much of this increased risk is determined by genetic factors.
Confirmation of the genetic vulnerability to SUD offers the possibility of early identification and targeted preventive interventions for ADHD patients at genetically increased risk for addiction. Treatment of children with ADHD with stimulant medication has shown some promise in diminishing but not eliminating the risk for later addiction Wilens et al., 2003) . A better understanding of the genetic underpinnings of addiction could help us identify which patients would benefit most from ADHD medication and which patients would be better served by other interventions.
We are very fortunate that this pilot study, using material from previous studies, yielded interesting results, meriting further investigation. However, in view of its limitations a cautious interpretation of the relevance of its results is warranted. The present study was executed with small study samples, leading to even smaller subgroups, restricting both 
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